drugset / Trial / NCT03583866

Adiposity and Endothelin Receptor Function

NCT03583866

RandomizedCrossoverDouble-blindTreatment

Summary

Elevated levels of ET-1 have been implicated in cardiovascular disease and some forms of hypertension. Due to the strong, positive correlation between obesity and hypertension, the present study will explore the contribution of adiposity in ETB receptor function and aim to elucidate if ETB receptor dysfunction is a major contributor to hypertension in obesity.

Timeline

Start
2018-05-21
Primary completion
2025-12
Completion
2026-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Candesartan Unknown 16 mg

Indications